Allergan Aesthetics Reports Aesthetic Treatment Satisfaction in Patients Using GLP-1s

Allergan Aesthetics reported results from two studies examining aesthetic treatment outcomes in adults taking GLP-1 and other medical weight-loss medications, finding improvements in patient satisfaction with facial appearance following treatment. The studies evaluated treatments commonly used to address facial volume loss and skin quality concerns that can accompany significant weight loss.

One study, called Harmony In Diversity, evaluated 30 adults taking GLP-1 medications who received a combination of hyaluronic acid fillers, onabotulinumtoxinA and a study-specific skincare regimen. Participants reported significant improvements in satisfaction with facial appearance, skin quality, psychological well-being and social function following treatment. According to the company, the study was the first to evaluate a neurotoxin combined with hyaluronic acid injectables in this patient population.

A second study, Halo, evaluated 25 adults taking GLP-1 medications who were treated with hyaluronic acid fillers across the face. An interim analysis found improvements in patient-reported satisfaction with facial appearance three months after treatment. Most participants reported that they still looked like themselves after treatment and were satisfied with how natural their results appeared. The majority of participants also reported satisfaction with their skin’s appearance.

Both studies used validated patient-reported outcome measures, including FACE-Q and SKIN-Q questionnaires, which are commonly used in aesthetic research to assess satisfaction and quality-of-life outcomes. Most treatment-related adverse events reported in both studies were mild and nonserious, according to the company.